Haleon (NYSE:HLN) Now Covered by HSBC

Equities researchers at HSBC initiated coverage on shares of Haleon (NYSE:HLN) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating on the stock.

Separately, Argus reissued a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Haleon Stock Performance

NYSE HLN opened at $8.12 on Wednesday. The company has a market capitalization of $37.08 billion, a price-to-earnings ratio of 29.00, a PEG ratio of 2.12 and a beta of 0.29. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. Haleon has a twelve month low of $7.70 and a twelve month high of $9.05. The stock has a fifty day simple moving average of $8.30 and a 200 day simple moving average of $8.29.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Barclays PLC grew its stake in Haleon by 56.4% during the second quarter. Barclays PLC now owns 3,317 shares of the company’s stock valued at $28,000 after acquiring an additional 1,196 shares in the last quarter. Hollencrest Capital Management grew its position in shares of Haleon by 21.5% during the 1st quarter. Hollencrest Capital Management now owns 7,114 shares of the company’s stock valued at $58,000 after purchasing an additional 1,258 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Haleon by 79.3% in the second quarter. Farther Finance Advisors LLC now owns 2,986 shares of the company’s stock worth $25,000 after purchasing an additional 1,321 shares during the period. Apollon Wealth Management LLC raised its position in shares of Haleon by 11.0% in the first quarter. Apollon Wealth Management LLC now owns 13,404 shares of the company’s stock worth $109,000 after buying an additional 1,332 shares in the last quarter. Finally, Financial Advocates Investment Management raised its position in shares of Haleon by 10.5% in the third quarter. Financial Advocates Investment Management now owns 14,849 shares of the company’s stock worth $124,000 after buying an additional 1,408 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.